Physician profile
Brian Parker
NPI 1174977383
$2,158.91
in general payments reported to CMS, 2019-2025
21 companies · $98.45 in 2025
The $98.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $361 · 2021: $580 · 2022: $335 · 2023: $404 · 2024: $253 · 2025: $98.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.36 | 2019-2024 | Wegovy, Ozempic |
| Abbvie INC. | $353.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $304.41 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $260.02 | 2020-2025 | |
| Astellas Pharma US INC | $110.26 | 2021-2024 | Veozah |
| Csl Behring | $107.53 | 2019-2021 | |
| Amgen INC. | $79.74 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $75.94 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $69.39 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $62.83 | 2020-2022 | |
| Esperion Therapeutics, INC. | $59.72 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $50.47 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.71 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $26.80 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $24.51 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $22.72 | 2024 | Euflexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $15.51 | 2022 | |
| Seqirus USA INC | $14.35 | 2020 | |
| Eisai INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.